Acelyrin Inc. — Cyborg Score 5/10

Strategic Profile

Acelyrin's pipeline was led by izokibep, a small therapeutic protein inhibitor of interleukin-17A (IL-17A) designed to overcome the limitations of monoclonal antibodies. Through the merger with Alumis, the combined company gained financial flexibility and runway to advance an expanded late-stage pipeline, now including lonigutamab.

Cyborg Score Rationale

Acelyrin had a differentiated immunology pipeline with late-stage candidates but faced capital constraints that led to the strategic merger. The combination with Alumis provided enhanced financial runway and portfolio depth, but the entity no longer exists as an independent public company.

Top Insights

• Acelyrin was co-founded in 2020 by Shao-Lee Lin and Bob Carey, combining physician-scientist and biopharma business development expertise
• The company secured $250 million in Series B financing in November 2021, followed by a $300 million Series C round in September 2022
• Acelyrin acquired ValenzaBio in January 2023 to bolster its immunology pipeline
• Acelyrin terminated its licensing agreement with Affibody AB for izokibep in February 2025

Recent Developments

• (February 2025) Announced definitive merger agreement with Alumis Inc.
• (May 2025) Completed merger with Alumis; ACELYRIN stock delisted from NASDAQ

Open the full interactive Acelyrin Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.